From Cullinan Oncology Emerges with $150M to Build Cancer Drug Portfolio:

Cullinan Oncology
Cullinan Oncology

Photo of Cullinan Oncology CEO Owen Hughes (l) and CSO Patrick Baeuerle (r) c/o Cullinan Oncology.